首页> 美国卫生研究院文献>Cell Division >Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1
【2h】

Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1

机译:Akt通过调节Skp2活性及其被APC / Cdh1破坏来寻找调节细胞周期的新途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Skp2 over-expression has been observed in many human cancers. However, the mechanisms underlying elevated Skp2 expression have remained elusive. We recently reported that Akt1, but not Akt2, directly controls Skp2 stability by interfering with its association with APC/Cdh1. As a result, Skp2 degradation is protected in cancer cells with elevated Akt activity. This finding expands our knowledge of how specific kinase cascades influence proteolysis governed by APC/Cdh1 complexes. However, it awaits further investigation to elucidate whether the PI3K/Akt circuit affects other APC/Cdh1 substrates. Our results further strengthen the argument that different Akt isoforms might have distinct, even opposing functions in the regulation of cell growth or migration. In addition, we noticed that Ser72 is localized in a putative Nuclear Localization Sequence (NLS), and that phosphorylation of Ser72 disrupts the NLS and thus promotes Skp2 cytoplasmic translocation. This finding links elevated Akt activity with the observed cytoplasmic Skp2 staining in aggressive breast and prostate cancer patients. Furthermore, it provides the rationale for the development of specific Akt1 inhibitors as efficient anti-cancer therapeutic agents.
机译:在许多人类癌症中已观察到Skp2过表达。但是,Skp2表达升高的潜在机制仍然难以捉摸。我们最近报道说,Akt1(而不是Akt2)通过干扰Skp2与APC / Cdh1的关联来直接控制Skp2的稳定性。结果,在具有升高的Akt活性的癌细胞中Skp2降解受到保护。这一发现扩展了我们对特定激酶级联如何影响由APC / Cdh1复合体控制的蛋白水解的知识。但是,有待进一步研究以阐明PI3K / Akt电路是否会影响其他APC / Cdh1基板。我们的结果进一步证明了不同的Akt亚型可能在调节细胞生长或迁移中具有独特的甚至相反的功能。此外,我们注意到Ser72位于假定的核定位序列(NLS)中,并且Ser72的磷酸化破坏了NLS,从而促进了Skp2细胞质易位。该发现将激进的Akt活性与在侵袭性乳腺癌和前列腺癌患者中观察到的细胞质Skp2染色联系起来。此外,它为开发特定的Akt1抑制剂作为有效的抗癌治疗剂提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号